Voyager Therapeutics, Inc.
VYGR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VYGR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VYGR
Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies and vectorized antibodies for neurological diseases, with lead programs in tau silencing (VY1706) and a Phase 1 trial for VY7523, supported by collaborations with Neurocrine and Novartis.
Key risk: Clinical development risks
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials for Voyager Therapeutics, Inc..
Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies and vectorized antibodies for neurological diseases, with lead programs in tau silencing (VY1706) and a Phase 1 trial for VY7523, supported by collaborations with Neurocrine and Novartis.
- Lead development candidate VY1706 for tau silencing gene therapy has achieved desired activity levels and been well-tolerated in preclinical studies [sec · filed 2025-02-11].
- Ongoing Phase 1 MAD clinical trial for VY7523 and planned Phase 1 clinical trial for VY1706 [sec_mda · as of 2026-08-06].
- Cash & equivalents of $38.5M as of 2026-06-30 [sec]; existing resources plus collaboration reimbursements expected to fund operations into 2028 [sec_mda · as of 2026-08-06].
- Accumulated deficit of $326.2 million as of December 31, 2024 [sec_mda · as of 2025-03-11].
- Collaborations with Neurocrine (GBA1 gene therapy program) and Novartis (Huntington's disease program) [sec_mda · as of 2026-03-09].
What works
- Lead tau silencing gene therapy candidate VY1706 has shown desired activity and tolerability in preclinical studies, supporting advancement to clinical trials [sec · filed 2025-02-11].
- Strategic collaborations with Neurocrine and Novartis provide reimbursement for development costs, extending cash runway [sec_mda · as of 2026-08-06].
- Cash runway projected into 2028 based on existing resources and collaboration income [sec_mda · as of 2026-08-06].
What to weigh
- Accumulated deficit of $326.2 million as of December 31, 2024, with expectations of continued significant expenses and operating losses [sec_mda · as of 2025-03-11].
- Net loss of $24.5M for the quarter ended 2026-06-30 [sec].
- Dependence on collaborations for funding; future capital requirements subject to many factors including clinical trial costs and program prioritization [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
VY1706 is the lead development candidate for tau silencing gene therapy with favorable preclinical profile.
“in 2026 for VY1706, the lead development candidate for its tau silencing gene therapy program, which has achieved desired activity levels and been well-tolerated in preclinical studies comparable to those conducted for VY9323.”
SEC filings · February 11, 2025
Cash runway is projected into 2028.
“to be sufficient to meet our planned operating expenses and capital expenditure requirements into 2028.”
SEC MD&A · August 6, 2026
Accumulated deficit was $326.2 million as of December 31, 2024.
“As of December 31, 2024, we had an accumulated deficit of $326.2 million.”
SEC MD&A · March 11, 2025
Risks & what to watch (3)›
Key risks
- Clinical development risks — VY7523 and VY1706 are in early clinical stages; failure could halt programs [sec_mda · as of 2026-08-06].
- Financial sustainability — Net loss of $24.5M and accumulated deficit of $326.2M; continued losses expected [sec] [sec_mda · as of 2025-03-11].
- Dependence on collaborations — Cash runway relies on reimbursements from Neurocrine and Novartis; changes could impact funding [sec_mda · as of 2026-08-06].
What to watch
- Initiation and data from Phase 1 clinical trial for VY1706 [sec_mda · as of 2026-08-06].
- Progress of ongoing Phase 1 MAD trial for VY7523 [sec_mda · as of 2026-08-06].
- Updates from Neurocrine and Novartis collaborations on GBA1 and Huntington's programs [sec_mda · as of 2026-03-09].
- Cash runway updates and potential need for additional financing [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Voyager Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Voyager Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.6 months
D/E 0.28 · 0% dilution
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
131
Total value held
$117.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,568,381 | $21.5M |
| vanguard capital management llc | 4,566,506 | $17.6M |
| armistice capital, llc | 3,500,000 | $13.5M |
| millennium management llc | 3,428,571 | $13.2M |
| geode capital management, llc | 1,049,978 | $4.1M |
| state street corp | 948,226 | $3.7M |
| dimensional fund advisors lp | 875,568 | $3.4M |
| vanguard portfolio management llc | 725,769 | $2.8M |
| morgan stanley | 681,711 | $2.6M |
| two sigma investments, lp | 615,660 | $2.4M |
Showing top 10 of 131 institutional holders of Voyager Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 7.1%
- Days to cover
- 6.8
- Shares short
- 3,663,210
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VYGR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Voyager Therapeutics, Inc.?
Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies and vectorized antibodies for neurological diseases, with lead programs in tau silencing (VY1706) and a Phase 1 trial for VY7523, supported by collaborations with Neurocrine and Novartis.
What is Voyager Therapeutics, Inc.'s lead drug candidate?
Voyager Therapeutics, Inc.'s most advanced tracked candidate is nbib-'223 (Preclinical) for Friedreich's ataxia.
Who is the CEO of Voyager Therapeutics, Inc.?
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. is the chief executive officer of Voyager Therapeutics, Inc. (VYGR).
Where is Voyager Therapeutics, Inc. headquartered?
Voyager Therapeutics, Inc. (VYGR) is headquartered in Lexington, MA, United States.
What therapeutic areas does Voyager Therapeutics, Inc. focus on?
Voyager Therapeutics, Inc. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.